TITLE

Biotech gets good news, twice

AUTHOR(S)
Henderson, Tom
PUB. DATE
June 2008
SOURCE
Crain's Detroit Business;6/23/2008, Vol. 24 Issue 25, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that according to Aastrom Biosciences Inc., the U.S. Food and Drug Administration has approved the use of cardiac repair cells for Phase II clinical trials of the treatment of dilated cardiomyopathy. Aastrom Biosciences makes regenerative medicines based on stem cells. The firm has also been given an extension of 180 days by the National Association of Securities Dealers Automated Quotations Systems (Nasdaq) to avoid delisting of its securities.
ACCESSION #
33203279

 

Related Articles

  • Biotech investment offers promise, pitfalls. JORDAN, CHRISTOPHER P. // Fairfield County Business Journal;2/15/2016, Vol. 52 Issue 7, p15 

    The article focuses on the benefits and opportunities offered by investing in the biotechnology industry despite reports from the NASDAQ Biotech Index on the decline in the industry in January 2016. It discusses the research conducted by The Independent Institute which found that only eight...

  • Week in Review.  // BioWorld Insight;4/1/2013, Vol. 21 Issue 14, p5 

    This section offers news briefs on the U.S. biotechnology industry. ARCA Biopharma Inc. has filed for a public offering. The phase III REVIVE trial of Aastrom Biosciences Inc. in critical limb ischemia has been terminated. The U.S. Food and Drug Administration (FDA) has approved the drug...

  • When will the bear move on? Brower, Vicki // EMBO Reports;Nov2002, Vol. 3 Issue 11, p1015 

    This article reports on problems faced by biotechnology industry in the U.S. in 2002. The year 2002 has not been kind to biotechnology: the industry has lost nearly half its value since January. Recent rejections of new drug applications from various bio-technology companies by the U.S. Food and...

  • Next Leg in hESC Race. Agres, Ted // Drug Discovery & Development;Mar2009, Vol. 12 Issue 3, p6 

    The article reports on the approval of a clinical trial, which involves a human embryonic stem cell (hESC)-based therapy, by the U.S. Food and Drug Administration (FDA). According to the article, the approval is depicted to be a triumph of science over politics and acclaims a much-needed...

  • CLINIC ROUNDUP.  // BioWorld Today;3/15/2007, Vol. 18 Issue 51, p3 

    The article offers news briefs on the biotechnology industry in the U.S. Avigen Inc. can already begin with its Phase II clinical development of AV650, a chemical entity in the U.S., since it already received an approval from the Food and Drug Administration. Montvale, New Jersey-based Memory...

  • CLINIC ROUNDUP.  // BioWorld Today;6/19/2008, Vol. 19 Issue 119, p10 

    This section offers news briefs on clinical trials in the biotechnology industry worldwide. Algeta ASA has began patient recruitment in a pivotal Phase III study of targeted therapeutic Alpharadin in advanced, hormone-refractory prostate cancer. Biopure Corp. announced that the U.S. Naval...

  • FDA, Research Organizations Seek to Bolster Drug Submissions. Wechsler, Jill // Applied Clinical Trials;Sep2013, Vol. 22 Issue 9, p12 

    The article informs that the U.S. Food and Drug Administration (FDA) has increased fees paid by pharma and biotech firms for 2014 authorized by the Prescription Drug User Fee Act (PDUFA). It states that decline in anticipated New Drug Applications (NDAs) submitted to the FDA can result in...

  • News In Brief. Waltz, Emily; Jones, Philip; Vermij, Peter; Katsnelson, Alla; Mitchell, Peter // Nature Biotechnology;Jun2006, Vol. 24 Issue 6, p601 

    The article offers news brief related to biotechnology industries in the U.S. A study conducted by the U.S. Food and Drug Administration found out a weak relationship between financial conflict and voting behavior among its members. The Syngenta International AG launched a Bioventure capital...

  • Stroke drug earns phase-3 trial. Walters, Kath // BRW;2/8/2007, Vol. 29 Issue 5, p12 

    The article reports that biotechnology company Neuren Pharmaceuticals Ltd. has received approval from the U.S. Food and Drug Administration (FDA) to begin a phase three drug trial of Glypromate, which is designed to prevent cognitive impairment in heart-surgery patients. If the trial is...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics